Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share holdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details an increase in the holding of Ordinary shares by a connected person, Ms. S Dexter, following the re-investment of a dividend paid on October 6, 2011, and the purchase of shares at 1374.50 pence per share on October 7, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: October 7, 2011 (purchase); February 1, 2012 (notification date).
- Individuals Involved: Dr. P J T Vallance (Director/PDMR) and Ms. S Dexter (Connected Person).
- Share Details: 73 Ordinary shares purchased at 1374.50 pence per share.
- Context: The transaction involved the re-investment of a dividend paid on October 6, 2011.